Sêmeia, a Toulouse-based medical telemonitoring company, has raised €21 million in a new funding round as it looks to extend its remote monitoring platform into additional disease areas and deepen its use of health data and artificial intelligence.
The round was backed by new investors Acton Capital, Mutuelles Impact and Citizen Capital, with existing backers Banque des Territoires and Orange Ventures also participating.
Founded in 2017, Sêmeia develops MedicWise, a CE IIA-certified medical device used by healthcare teams across France for remote patient monitoring, chronic disease management and clinical research. The company said the new capital will support expansion into new pathologies, the development of services for care and research, new medical studies, and further external growth.
The deal highlights continued investor interest in digital health platforms that combine remote care infrastructure with data-driven clinical tools, particularly as healthcare systems look for new ways to manage chronic disease at scale.
The round was backed by new investors Acton Capital, Mutuelles Impact and Citizen Capital, with existing backers Banque des Territoires and Orange Ventures also participating.
Founded in 2017, Sêmeia develops MedicWise, a CE IIA-certified medical device used by healthcare teams across France for remote patient monitoring, chronic disease management and clinical research. The company said the new capital will support expansion into new pathologies, the development of services for care and research, new medical studies, and further external growth.
The deal highlights continued investor interest in digital health platforms that combine remote care infrastructure with data-driven clinical tools, particularly as healthcare systems look for new ways to manage chronic disease at scale.